Oral tranexamic acid lightens refractory melasma

Melasma is a common acquired hyperpigmentary disorder, particularly among Asians and Hispanics, but its exact pathomechanism is poorly understood. Tranexamic acid has been found to lighten melasma by interfering with the interaction of melanocytes and keratinocytes by inhibiting the plasminogen/plasmin system. The aim was to evaluate the therapeutic effects of oral tranexamic acid in the treatment of melasma refractory to topical skin‐lightening agents.

[1]  M. Timalsina,et al.  Oral tranexamic acid for the treatment of melasma , 2018, Clincal and Experimental Dermatology.

[2]  M. Cicardi,et al.  The safety of treatments for angioedema with hereditary C1 inhibitor deficiency , 2015, Expert opinion on drug safety.

[3]  A. Gompel,et al.  Tranexamic acid as maintenance treatment for non‐histaminergic angioedema: analysis of efficacy and safety in 37 patients , 2014, Clinical and experimental immunology.

[4]  Q. Sun,et al.  Treatment of melasma with oral administration of compound tranexamic acid: a preliminary clinical trial , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  Mira Choi,et al.  Role of oral tranexamic acid in melasma patients treated with IPL and low fluence QS Nd:YAG laser , 2013, The Journal of dermatological treatment.

[6]  J. H. Lee,et al.  Oral Tranexamic Acid Enhances the Efficacy of Low‐Fluence 1064‐Nm Quality‐Switched Neodymium‐Doped Yttrium Aluminum Garnet Laser Treatment for Melasma in Koreans: A Randomized, Prospective Trial , 2013, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[7]  W. Aberer,et al.  International consensus on hereditary and acquired angioedema. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[8]  Yi Sun,et al.  Treatment of Melasma With Oral Administration of Tranexamic Acid , 2012, Aesthetic Plastic Surgery.

[9]  A. Manosroi,et al.  Topical 5% tranexamic acid for the treatment of melasma in Asians: A double-blind randomized controlled clinical trial , 2012, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[10]  H. Y. Kang,et al.  Defective barrier function in melasma skin , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  Vaneeta M. Sheth,et al.  Melasma: a comprehensive update: part I. , 2011, Journal of the American Academy of Dermatology.

[12]  J. Ortonne,et al.  Transcriptional profiling shows altered expression of wnt pathway- and lipid metabolism-related genes as well as melanogenesis-related genes in melasma. , 2011, The Journal of investigative dermatology.

[13]  S. Zahler,et al.  Plasmin Inhibitors Prevent Leukocyte Accumulation and Remodeling Events in the Postischemic Microvasculature , 2011, PloS one.

[14]  P. Grimes,et al.  Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma. , 2010, Journal of the American Academy of Dermatology.

[15]  Jinfen Liu,et al.  Tranexamic acid can treat ultraviolet radiation-induced pigmentation in guinea pigs. , 2010, European journal of dermatology : EJD.

[16]  N. Ferrara.  Binding to the Extracellular Matrix and Proteolytic Processing: Two Key Mechanisms Regulating Vascular Endothelial Growth Factor Action , 2010, Molecular biology of the cell.

[17]  E. Crivellato,et al.  Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. , 2008, Cancer letters.

[18]  H. Kido,et al.  Mast cell tryptase and photoaging: possible involvement in the degradation of extra cellular matrix and basement membrane proteins , 2008, Archives of Dermatological Research.

[19]  Eun-So Lee,et al.  The vascular characteristics of melasma. , 2007, Journal of dermatological science.

[20]  Mi-Yeon Kim,et al.  Localized Intradermal Microinjection of Tranexamic Acid for Treatment of Melasma in Asian Patients: A Preliminary Clinical Trial , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[21]  G. Montalescot,et al.  Acute myocardial infarction after oral tranexamic acid treatment initiation. , 2002, International journal of cardiology.

[22]  S. Lethagen,et al.  No Increased Risk of Venous Thrombosis in Women Taking Tranexamic Acid , 2001, Thrombosis and Haemostasis.

[23]  K. Maeda,et al.  Topical trans-4-aminomethylcyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. , 1998, Journal of photochemistry and photobiology. B, Biology.

[24]  P. Dell’Era,et al.  Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[25]  K. Woo,et al.  Massive pulmonary thromboembolism after tranexamic acid antifibrinolytic therapy , 1989, The British journal of clinical practice.

[26]  A. Miura,et al.  Deep-vein thrombosis induced by tranexamic acid in idiopathic thrombocytopenic purpura. , 1988, JAMA.

[27]  N. Higashi.  Treatment of Melasma with Oral Tranexamic Acid , 1988 .